Dr. Anita Turk, MD
Claim this profileIndiana University/Melvin and Bren Simon Cancer Center
Studies Pancreatic Cancer
Studies Cancer
11 reported clinical trials
22 drugs studied
Area of expertise
1Pancreatic Cancer
Stage IV
BRCA1 positive
BRCA2 positive
2Cancer
Stage III
Stage IV
BRCA1 positive
Affiliated Hospitals
Indiana University/Melvin And Bren Simon Cancer Center
IU Health North Hospital
Clinical Trials Anita Turk, MD is currently running
Combination Chemotherapy
for Biliary Tract Cancer
This trial is testing a new combination of three drugs for patients with advanced biliary tract cancers who did not respond well to their first treatment. The drugs work together to damage the cancer cells' DNA and stop them from growing. The goal is to find a better second-line treatment for these patients. Previous tests with similar drugs did not show improvement.
Recruiting1 award Phase 29 criteria
Pembrolizumab + Olaparib
for Pancreatic Cancer
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cell's genetic material. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to some types of cancer, including pancreatic cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of pembrolizumab to the usual treatment of olaparib may help to shrink tumors in patients with metastatic pancreatic cancer with BRCA1 or BRCA2 mutations.
Recruiting1 award Phase 237 criteria
More about Anita Turk, MD
Clinical Trial Related5 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Anita Turk, MD has experience with
- Liposomal Irinotecan
- Fluorouracil
- Atezolizumab
- Nab-paclitaxel
- Oxaliplatin
- Leucovorin
Breakdown of trials Anita Turk, MD has run
Pancreatic Cancer
Cancer
Colorectal Cancer
Adenocarcinoma
Pancreatic Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Anita Turk, MD specialize in?
Anita Turk, MD focuses on Pancreatic Cancer and Cancer. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are BRCA1 positive.
Is Anita Turk, MD currently recruiting for clinical trials?
Yes, Anita Turk, MD is currently recruiting for 3 clinical trials in Indianapolis Indiana. If you're interested in participating, you should apply.
Are there any treatments that Anita Turk, MD has studied deeply?
Yes, Anita Turk, MD has studied treatments such as Liposomal Irinotecan, Fluorouracil, Atezolizumab.
What is the best way to schedule an appointment with Anita Turk, MD?
Apply for one of the trials that Anita Turk, MD is conducting.
What is the office address of Anita Turk, MD?
The office of Anita Turk, MD is located at: Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana 46202 United States. This is the address for their practice at the Indiana University/Melvin and Bren Simon Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.